Protalix Biotherapeutics Inc (PLX) Key Ratios
$2.62
As on 03-Sep-2026 16:00EDT
Market cap
$192 Mln
Revenue (TTM)
$81 Mln
P/E Ratio
10.3
P/B Ratio
2.7
Div. Yield
0 %
Key Ratios and Highlights
| Growth Score (%) | Quarterly | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | QoQ | YoY | 1-Year | 3-Years | 5-Years |
| Revenue | -41.05 | 27.07 | 30.14 | 6.12 | 10.91 |
| EBIT | -74.90 | 270.78 | 169.16 | 23.32 | 32.45 |
| Net Profit | -79.38 | 2,203.05 | 201.91 | 28.63 | 23.84 |
| EPS | -79.26 | 2,167.00 | 201.54 | 89.61 | 19.57 |
| Book Value | -- | -- | 15.18 | -- | -- |
| Key Ratios (%) | Average | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | 3-Years | 5-Years | TTM | Dec-25 | Dec-24 |
| EBIT-Margin
| 6.44 | -11.58 | 30.66 | -8.37 | 9.77 |
| Net Margin
| -- | -- | 23.50 | -- | -- |
| Return on equity
| 21.90 | 82.30 | 31.67 | -14.44 | 7.64 |
| Return on Capital
| 4.19 | -26.39 | -- | -12.54 | 5.33 |
| Return on Assets
| 2.36 | -10.99 | 12.42 | -8.48 | 3.71 |
| Debt to Equity (x)
| -- | -- | 0.00 | 0.17 | 0.13 |
Profitability
ROCE
--
--
Earning before interest and taxes / (Average net worth + Average total Debt) * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Protalix Biotherapeutics Inc (PLX)
|
--
|
-12.54
|
5.33
|
19.77
|
-59.39
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
ROE
31.67
Higher than Peers by 72.07
Profit after tax / Average Net worth * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Protalix Biotherapeutics Inc (PLX)
|
31.67
|
-14.44
|
7.64
|
72.50
|
179.02
|
|
Peer Median
|
-40.40
|
--
|
--
|
--
|
--
|
ROA
12.42
Higher than Peers by 43.40
Profit after tax / Average Total assets * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Protalix Biotherapeutics Inc (PLX)
|
12.42
|
-8.48
|
3.71
|
11.86
|
-23.06
|
|
Peer Median
|
-30.98
|
--
|
--
|
--
|
--
|
EBIT Margin
30.66
Higher than Peers by 114.27
Operating profit (EBIT) / Net Sales * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Protalix Biotherapeutics Inc (PLX)
|
30.66
|
-8.37
|
9.77
|
17.93
|
-24.91
|
|
Peer Median
|
-83.62
|
--
|
--
|
--
|
--
|
Net Margin
23.50
Higher than Peers by 116.17
Net profit / Total Income (Net sales plus other income) * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Protalix Biotherapeutics Inc (PLX)
|
23.50
|
-12.52
|
5.49
|
12.69
|
-31.33
|
|
Peer Median
|
-92.67
|
--
|
--
|
--
|
--
|
Cash Profit Margin
0.00
Higher than Peers by 0.00
(Net profit + Depreciation) / Gross Sales * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Protalix Biotherapeutics Inc (PLX)
|
0.00
|
--
|
--
|
--
|
--
|
|
Peer Median
|
0.00
|
--
|
--
|
--
|
--
|
Revenue Growth
30.14
Lower than Peers by 23.81
Year on year growth in net sales
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Protalix Biotherapeutics Inc (PLX)
|
30.14
|
-0.01
|
-0.18
|
0.37
|
0.24
|
|
Peer Median
|
53.95
|
--
|
--
|
--
|
--
|
EBIT Growth
169.16
Higher than Peers by 169.96
Year on year growth in operating profit (EBIT)
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Protalix Biotherapeutics Inc (PLX)
|
169.16
|
-184.68
|
-55.59
|
198.97
|
40.84
|
|
Peer Median
|
-0.80
|
--
|
--
|
--
|
--
|
Net Profit Growth
201.91
Higher than Peers by 209.21
Year on year growth in profit after tax
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Protalix Biotherapeutics Inc (PLX)
|
201.91
|
-325.24
|
-64.73
|
155.68
|
45.88
|
|
Peer Median
|
-7.30
|
--
|
--
|
--
|
--
|
EPS Growth
201.54
Higher than Peers by 186.89
Year on year growth in earnings per share
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Protalix Biotherapeutics Inc (PLX)
|
201.54
|
-3.32
|
-0.68
|
1.39
|
0.52
|
|
Peer Median
|
14.65
|
--
|
--
|
--
|
--
|
Book Value Growth
40.85
Higher than Peers by 51.03
Year on year growth in book value per share
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Protalix Biotherapeutics Inc (PLX)
|
40.85
|
--
|
--
|
--
|
--
|
|
Peer Median
|
-10.18
|
--
|
--
|
--
|
--
|
Solvency
Debt to Equity
--
--
Total debt / Net worth
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Protalix Biotherapeutics Inc (PLX)
|
--
|
0.17
|
0.13
|
0.82
|
-3.15
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Short term debt to equity ratio
0.02
--
(Short term borrowings / Net worth)
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Protalix Biotherapeutics Inc (PLX)
|
0.02
|
0.03
|
0.03
|
0.69
|
-0.11
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Current Ratio
2.94
Lower than Peers by 2.87
Current Assets / Current Liabilities and Provisions
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Protalix Biotherapeutics Inc (PLX)
|
2.94
|
2.51
|
2.34
|
1.54
|
1.38
|
|
Peer Median
|
5.81
|
--
|
--
|
--
|
--
|
Quick Ratio
1.91
Lower than Peers by 3.79
(Current Assets - Inventory) / Current Liabilities and Provisions
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Protalix Biotherapeutics Inc (PLX)
|
1.91
|
1.54
|
1.52
|
1.12
|
0.87
|
|
Peer Median
|
5.70
|
--
|
--
|
--
|
--
|
Interest Coverage
19.77
Higher than Peers by 21.86
Earning before interest and taxes (EBIT) / Interest Expenses
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Protalix Biotherapeutics Inc (PLX)
|
19.77
|
-3.71
|
4.91
|
3.69
|
-4.69
|
|
Peer Median
|
-2.09
|
--
|
--
|
--
|
--
|
Operating Efficiency
Debtors to sales
20.47
Higher than Peers by 1.33
Debtors outstanding / Net Sales * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Protalix Biotherapeutics Inc (PLX)
|
20.47
|
16.76
|
5.45
|
8.05
|
9.63
|
|
Peer Median
|
19.14
|
--
|
--
|
--
|
--
|
Asset Turnover
0.53
Higher than Peers by 0.46
Sales / Average Total Assets
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Protalix Biotherapeutics Inc (PLX)
|
0.53
|
0.68
|
0.68
|
0.93
|
0.74
|
|
Peer Median
|
0.06
|
--
|
--
|
--
|
--
|
Receivable days
--
--
Average Debtors / Sales * 365
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Protalix Biotherapeutics Inc (PLX)
|
--
|
40.68
|
27.98
|
27.49
|
30.78
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Inventory Days
--
--
Average Inventory / Sales * 365
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Protalix Biotherapeutics Inc (PLX)
|
--
|
311.85
|
302.55
|
284.87
|
323.99
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Payable days
--
--
Average Creditors / Cost of goods sold * 365
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Protalix Biotherapeutics Inc (PLX)
|
--
|
65.01
|
66.48
|
80.91
|
119.76
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Cash Conversion Cycle
--
--
Receivable Days + Inventory Days - Payable Days
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Protalix Biotherapeutics Inc (PLX)
|
--
|
287.52
|
264.04
|
231.45
|
235.01
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Valuation
Price / Earnings
10.35
--
Current share price divided by earning per share in the last twelve months
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Protalix Biotherapeutics Inc (PLX)
|
10.35
|
-21.41
|
51.97
|
15.62
|
-4.71
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Price / Book Value
2.65
Lower than Peers by 2.53
Current share price divided by book value per share in the latest financial year
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Protalix Biotherapeutics Inc (PLX)
|
2.65
|
2.93
|
3.53
|
3.87
|
-6.61
|
|
Peer Median
|
5.18
|
--
|
--
|
--
|
--
|
Dividend Yield
--
--
Dividend per share in the past twelve months divided by current share price
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Protalix Biotherapeutics Inc (PLX)
|
--
|
--
|
--
|
--
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
EV/EBITDA
6.01
--
Enterprise Value (Current Market Capitalisation + Total Debt - Cash & Equivalents) / Earnings before interest, taxes, depreciation and taxes (EBITDA)
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Protalix Biotherapeutics Inc (PLX)
|
6.01
|
-40.46
|
18.88
|
8.73
|
-7.57
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Market Cap
192
Higher than Peers by 46
Current Share price multiplied by latest total number of shares outstanding
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Protalix Biotherapeutics Inc (PLX)
|
192
|
--
|
--
|
--
|
--
|
|
Peer Median
|
146
|
--
|
--
|
--
|
--
|